Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Debt
Debt-to-Equity Ratio0.01
Current Ratio4.34
Quick Ratio4.32
Price-To-Earnings
Trailing P/E Ratio105.10
Forward P/E Ratio158.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.54 billion
Price / Sales9.45
Cash Flow$0.8754 per share
Price / Cash78.00
Book Value$7.73 per share
Price / Book8.83
Profitability
EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-5.92%
Return on Equity1.74%
Return on Assets1.25%
Miscellaneous
Employees1,208
Outstanding Shares212,580,000
Market Cap$14.42 billion
Incyte (NASDAQ:INCY) Frequently Asked Questions
What is Incyte's stock symbol?
Incyte trades on the NASDAQ under the ticker symbol "INCY."
How were Incyte's earnings last quarter?
Incyte Co. (NASDAQ:INCY) issued its earnings results on Tuesday, July, 31st. The biopharmaceutical company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.22. The biopharmaceutical company had revenue of $521.50 million for the quarter, compared to the consensus estimate of $510.70 million. Incyte had a positive return on equity of 1.74% and a negative net margin of 5.92%. The company's revenue was up 59.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) earnings per share. View Incyte's Earnings History.
When is Incyte's next earnings date?
What price target have analysts set for INCY?
23 brokers have issued 12 month target prices for Incyte's stock. Their forecasts range from $70.00 to $172.00. On average, they expect Incyte's share price to reach $101.7712 in the next year. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Price Targets for Incyte.
What is the consensus analysts' recommendation for Incyte?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 8 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.
What are Wall Street analysts saying about Incyte stock?
Here are some recent quotes from research analysts about Incyte stock:
- 1. JPMorgan Chase & Co. analysts commented, "INCY’s 1Q print/report (initial thoughts here; slides here) this morning was relatively uneventful. Following the success of REACH1 in acute GVHD, management is planning a regulatory filing in 3Q18 (recall Jakafi has BTD status) with plans for an immediate launch upon approval. Also, as previously disclosed, a filing for the FGFR inhibitor in cholangiocarcinoma is still anticipated in 2019, pending final data follow- up (interim data at recent investor day). We’re maintaining our OW given shares are trading at a discount to our DCF derived fair value for the base business. With that said, we suspect it will require some significant execution on the relatively broad pipeline for investors to more actively re-engage with the story." (8/1/2018)
- 2. Raymond James analysts commented, "We are maintaining our Outperform rating for Incyte. Recently, Novartis reported Jakavi sales of $239 million for 2Q18, showcasing continued strong year-over-year growth, although the revenues were slightly lower than consensus estimates of $245 million (in line with our estimate of $240 million). Separately, Lilly reported Olumiant sales of $45 million worldwide (consensus of $47 million versus our estimate of $35 million), representing a growth of ~40% since 1Q18. Given the growing Jakafi franchise, a burgeoning pipeline addressing significant market opportunities that is largely not appreciated by most investors, and a cash position of $1.3 billion (pro forma), we continue to recommend shares of INCY to long-term, risk-tolerant investors." (7/27/2018)
- 3. According to Zacks Investment Research, "Incyte's Jakafi continues to drive growth propelled by increase in patient demand. Jakafi’s performance is expected to get a further boost with a potential label expansion. Incyte expects to submit an sNDA seeking approval of Jakafi in patients with steroid-refractory acute graft-versus-host disease in the second half of 2018. The recent FDA approval of Olumiant 2 mg will further boost investor sentiment as Incyte received milestone payment from Lilly. However, Incyte suffered a huge setback with failure of the phase III study, ECHO-301, evaluating epacadostat in combination with Keytruda as it was one of the most promising candidates. Further, the approval of the 4mg dose of baricitinib is also doubtful. Moreover, Incyte’s dependence on only Jakafi is concerning. Shares have underperformed the industry in the last six months." (7/23/2018)
Who are some of Incyte's key competitors?
Some companies that are related to Incyte include Iqvia (IQV), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and VIRALYTICS Ltd/S (VRACY).
Who are Incyte's key executives?
Incyte's management team includes the folowing people:
- Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
- Mr. David W. Gryska M.B.A., MBA, Exec. VP & CFO (Age 63)
- Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
- Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
- Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)
Has Incyte been receiving favorable news coverage?
News stories about INCY stock have been trending somewhat positive on Friday, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte earned a daily sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Incyte.
Who are Incyte's major shareholders?
Incyte's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (16.11%), BlackRock Inc. (6.81%), Manning & Napier Group LLC (2.02%), BB Biotech AG (1.77%), Northern Trust Corp (0.90%) and Bank of New York Mellon Corp (0.63%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein and Vijay K Iyengar. View Institutional Ownership Trends for Incyte.
Which major investors are selling Incyte stock?
INCY stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Jennison Associates LLC, Massachusetts Financial Services Co. MA, Bellevue Group AG, Retirement Systems of Alabama and Victory Capital Management Inc.. Company insiders that have sold Incyte company stock in the last year include David W Gryska, Paul A Friedman, Paula J Swain, Reid M Huber and Vijay K Iyengar. View Insider Buying and Selling for Incyte.
Which major investors are buying Incyte stock?
INCY stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Point72 Asset Management L.P., Frontier Capital Management Co. LLC, Orbimed Advisors LLC, First Trust Advisors LP, Country Trust Bank, Canada Pension Plan Investment Board and Rhenman & Partners Asset Management AB. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.
How do I buy shares of Incyte?
Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Incyte's stock price today?
One share of INCY stock can currently be purchased for approximately $68.28.
How big of a company is Incyte?
Incyte has a market capitalization of $14.42 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.
How can I contact Incyte?
Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]
MarketBeat Community Rating for Incyte (NASDAQ INCY)
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
